On March 17, 2026, Arcus Biosciences, Inc. announced the resignation of Jennifer Jarrett from her role as Chief Operating Officer, effective March 30, 2026. The company clarified that her departure was not due to any disagreements regarding the company's operations, policies, or practices. Following her resignation, Arcus and Ms. Jarrett entered into a separation agreement that includes provisions for her to provide advisory services until June 30, 2026. As part of this agreement, the company will extend the post-termination option exercise period for any vested options she holds to a total of twelve months. The separation agreement also includes a standard release of claims. This development may raise concerns regarding leadership stability at Arcus, which could impact investor confidence and operational execution in the near term. The company plans to disclose further details regarding the separation agreement in its upcoming quarterly filing on Form 10-Q.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.